United States:
FDA Determines Levonorgestrel Drug Not Withdrawn For Reasons Of Safety Or Effectiveness
15 September 2014
Jones Day
To print this article, all you need is to be registered or login on Mondaq.com.
Since the last Jones Day Update, FDA determined that JADELLE (levonorgestrel) Implant, 75mg was not
withdrawn for reasons of safety or effectiveness. This
determination will allow FDA to approve abbreviated new drug
applications for the drug, if all other legal and regulatory
requirements are met.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Food, Drugs, Healthcare, Life Sciences from United States
Manatt Health: Health AI Policy Tracker
Manatt, Phelps & Phillips LLP
The purpose of this quarterly tracker is to identify key federal and state health AI policy activity. Below reflects federal legislative and regulatory activity to date related to AI...